NCT06343064 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
| NCT ID | NCT06343064 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Avistone Biotechnology Co., Ltd. |
| Condition | Non-Small-Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2023-06-13 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 156 participants in total. It began in 2023-06-13 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Eligibility Criteria
Inclusion Criteria: 1. Ability to understand and willingness to sign a written informed consent document. 2. Aged at least 18 years old. 3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV). 4. EGFR mutations, including exon 19 deletion and exon 21 L858R. 5. C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI. 6. At least one measurable lesion as defined by RECIST V1.1. 7. ECOG performance status 0 to 1. Exclusion Criteria: 1. Previous treatment with MET inhibitors or HGF-targeted therapy. 2. There are mutations of ALK or ROS1. 3. Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control. 4. Pregnant or nursing women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06343064 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small-Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06343064 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06343064 currently recruiting?
Yes, NCT06343064 is actively recruiting participants. Contact the research team at linliang@avistonebio.com for enrollment information.
Where is the NCT06343064 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06343064 clinical trial?
NCT06343064 is sponsored by Avistone Biotechnology Co., Ltd.. The trial plans to enroll 156 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.